復星醫藥(02196.HK):mRNA新冠疫苗BNT162b2獲澳門衞生局特別許可進口批准
格隆匯 2 月 25日丨復星醫藥(02196.HK)公吿,2021年2月23日,mRNA新冠疫苗BNT162b2(以下簡稱“該疫苗”)獲得中國澳門特別行政區(以下簡稱“中國澳門”)衞生局特別許可進口批准、供中國澳門衞生局使用於當地新冠病毒疫苗接種計劃,所涉疫苗數量不超過10.5萬劑(以下簡稱“本次特別進口許可”)。
中國澳門政府已計劃採購共計40萬劑(包括本次特別進口許可數量在內)mRNA新冠疫苗BNT162b2用於當地新冠病毒疫苗接種計劃,本次特別進口許可以外的其餘部分,將根據中國澳門政府新冠病毒疫苗接種計劃的實施需求等再次申請並進行審批。
BNT162b2系基於《許可協議》引進區域內的候選mRNA新冠疫苗一,擬主要用於預防新型冠狀病毒肺炎。截至本公吿日,該疫苗已於中國香港獲認可作緊急使用、於中國大陸尚處於Ⅱ期臨牀試驗階段。
截至公吿日,除該疫苗外,於中國澳門獲批進口使用於新冠病毒疫苗接種計劃的疫苗為國藥集團中國生物集團北京生物製品研究所新型冠狀病毒滅活疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.